Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics and the ECOG-ACRIN Cancer Research Group entered a clinical trial collaboration to run EA2251, a registration-enabling Phase II/III study of ivonescimab plus chemotherapy in first-line advanced biliary tract cancer. The study is the 7th international registrational trial for ivonescimab and the second Phase III registrational study in BTC; US site activations are expected to begin in Q4 2026.
Key figures
- Drug Name
- ivonescimab
- Phase Of Trial
- Phase II/III
- Study
- EA2251
- Nct id
- NCT07765433
- Site activation timing
- Q4 2026
- Registrational trials count
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.